Sharkey John W.
Known title: VP, Business DevelopmentCIK: 0001515991
Sharkey John W.'s purchase track record
Sharkey John W. has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/10/2025 | GOVX | $6K | -29.9% | -36.9% | +27.9% |
| 7/1/2022 | GOVX | $820 | +34.6% | -22.2% | +0.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| GOVX | ▲ Buy | Open Market | 6,000 | $6K | 4/10/2025 | View on chart |
| GOVX | ▲ Buy | Open Market | 1,000 | $820 | 7/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
GeoVax Notes Sustained Clade Ib Mpox Transmission in US
GeoVax Labs reported that Clade Ib mpox transmission in the United States is likely to be sustained. This development is relevant as the company focuses on mpox-related solutions. The stock currently trades near its 52-week low, reflecting broader market conditions.
GeoVax Notes Sustained Clade Ib Mpox Transmission in US. GeoVax Labs reported that Clade Ib mpox transmission in the United States is likely to be sustained. This development is relevant as the company focuses on mpox-related solutions. The stock currently trades near its 52-week low, reflecting broader market conditions.